These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24282029)

  • 1. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.
    Gordon AS; Tabor HK; Johnson AD; Snively BM; Assimes TL; Auer PL; Ioannidis JP; Peters U; Robinson JG; Sucheston LE; Wang D; Sotoodehnia N; Rotter JI; Psaty BM; Jackson RD; Herrington DM; O'Donnell CJ; Reiner AP; Rich SS; Rieder MJ; Bamshad MJ; Nickerson DA;
    Hum Mol Genet; 2014 Apr; 23(8):1957-63. PubMed ID: 24282029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
    Zhou Y; Ingelman-Sundberg M; Lauschke VM
    Clin Pharmacol Ther; 2017 Oct; 102(4):688-700. PubMed ID: 28378927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Māori.
    Lea RA; Roberts RL; Green MR; Kennedy MA; Chambers GK
    N Z Med J; 2008 Apr; 121(1272):33-7. PubMed ID: 18425152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.
    Makeeva O; Stepanov V; Puzyrev V; Goldstein DB; Grossman I
    Pharmacogenomics; 2008 Jul; 9(7):847-68. PubMed ID: 18597650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.
    Solus JF; Arietta BJ; Harris JR; Sexton DP; Steward JQ; McMunn C; Ihrie P; Mehall JM; Edwards TL; Dawson EP
    Pharmacogenomics; 2004 Oct; 5(7):895-931. PubMed ID: 15469410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
    Klotz U
    Clin Pharmacokinet; 2007; 46(4):271-9. PubMed ID: 17375979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of the cytochromes P450.
    Daly AK
    Curr Top Med Chem; 2004; 4(16):1733-44. PubMed ID: 15579105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development.
    Rajman I; Knapp L; Morgan T; Masimirembwa C
    EBioMedicine; 2017 Mar; 17():67-74. PubMed ID: 28237373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects.
    Sim SC; Ingelman-Sundberg M
    Hum Genomics; 2010 Apr; 4(4):278-81. PubMed ID: 20511141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of cytochrome P450 (CYP) in the elderly.
    Seripa D; Pilotto A; Panza F; Matera MG; Pilotto A
    Ageing Res Rev; 2010 Oct; 9(4):457-74. PubMed ID: 20601196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.
    Kim YM; Yoo SH; Kang RY; Kim MJ; Bae YY; Lee YK; Jeon SJ; Chon KJ; Shin SM; Kim SG; Park KH; Son IJ
    Am J Health Syst Pharm; 2007 Jan; 64(2):166-75. PubMed ID: 17215467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of drug-metabolizing enzymes in Italian populations.
    Serpe L; Canaparo R; Scordo MG; Spina E
    Drug Metab Pers Ther; 2015 Jun; 30(2):107-20. PubMed ID: 25527811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
    Hart SN; Zhong XB
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics.
    Wolf CR; Smith G
    Br Med Bull; 1999; 55(2):366-86. PubMed ID: 10723863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
    Linder MW; Prough RA; Valdes R
    Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
    Zhou Y; Lauschke VM
    Pharmacogenomics J; 2022 Dec; 22(5-6):284-293. PubMed ID: 36068297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.